Vaxcyte
PCVX
197 hedge funds and large institutions have $5B invested in Vaxcyte in 2023 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 106 increasing their positions, 39 reducing their positions, and 25 closing their positions.
172% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 39
58% more capital invested
Capital invested by funds: $3.15B → $5B (+$1.84B)
48% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 25
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
5% more funds holding
Funds holding: 187 → 197 (+10)
1.69% more ownership
Funds ownership: 105.08% → 106.77% (+1.7%)
75% less call options, than puts
Call options by funds: $6.1M | Put options by funds: $24.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$107M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$102M |
| 3 |
BlackRock
New York
|
+$94M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$85.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$80.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$72.1M |
| 2 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$44.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$40.5M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$21.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.8M |
PCVX Hedge Fund Activity: Q2 2023 in Review
197 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2023, worth a combined $5B — up 58% from $3.15B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PCVX positions and 25 closed out — a net gain of 12 holders — while 106 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $107M. The largest seller was Carlyle Group, exiting entirely with an estimated $72.1M sold.
- 197 institutional investors held Vaxcyte (PCVX) as of Q2 2023, up from 187 in Q1 2023.
- Funds reported $5B of Vaxcyte stock for Q2 2023, up 58% quarter-over-quarter.
- 37 funds opened new Vaxcyte positions in Q2 2023 and 25 closed out, a net change of +12 holders.
- The largest Vaxcyte buyer in Q2 2023 was Fidelity Investments, an estimated $107M added.
- The largest Vaxcyte seller in Q2 2023 was Carlyle Group, an estimated $72.1M sold.
Based on aggregated 13F filings for Q2 2023.